Trial Profile
Clinical Trials Insight: 700023814
Status:
Planning
Phase of Trial:
Phase III
Latest Information Update: 28 Nov 2008
Price :
$35
*
At a glance
- Drugs Thymalfasin (Primary) ; Antineoplastics
- Indications Malignant melanoma
- Focus Registrational; Therapeutic Use
- Sponsors SciClone Pharmaceuticals
- 17 Nov 2008 Agreement reached with US FDA on Special Protocol Assessment.
- 20 Nov 2007 Planned start date adjusted from Q4 2007 to Q1 2008.
- 14 Jun 2007 New trial record.